Catalyst Dossier · compiled by CeliA 🧫

MYLAN (VTRS)

Pharmaceutical Preparations · market cap $17.9B · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-17

NDA Filing

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Viatris Inc. (VTRS) is a global generics and branded pharmaceutical company formed in 2020 via the merger of Mylan and Upjohn (Pfizer's legacy off-patent brands division), headquartered in Canonsburg, PA, with ~32,000 employees and an $18.9B market cap. The company carries a substantial $12.5B net debt load against $1.8B cash, with revenues declining from $17.9B in 2021 to $14.3B in 2025 and a $3.5B net loss in 2025. Near-term catalysts center on an NDA filing in October 2026 and two Phase 3 readouts for transdermal progestin contraceptive systems in early-to-mid 2027.

The catalyst path

2026-10-17NDA Filingimp 7/10
2026-11-30 (est.)Phase 2 · MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)imp 7/10
2026-12-31Phase 3imp 8/10
2027-03-15 (est.)Phase 3 · Transdermal system containing progestinimp 9/10
2027-05-15 (est.)Phase 3 · Transdermal system containing progestinimp 9/10

Pipeline

Asset	Phase	Indication
Amlodipine/atorvastatin single pill	Phase 3	Hypertension
MYL-1601D Product	Phase 3	Diabetes Mellitus, Type 1
venlafaxine ER 75 mg/day (fixed dose)	Phase 3	Major Depressive Disorder
LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION	Phase 3	Glaucoma, Primary Open Angle (POAG)
Revefenacin	Phase 3	Chronic Obstructive Pulmonary Disease, COPD
Econazole Nitrate Cream, 1%	Phase 3	Tinea Pedis
Eletriptan 20 mg	Phase 3	Migraine With or Without Aura
Eletriptan 80 mg	Phase 3	Migraine With or Without Aura
TD-4208 700 μg	Phase 2	Chronic Obstructive Pulmonary Disease, COPD
MR-107A-01	Phase 2	Pain
pramipexole	Phase 3	Restless Legs Syndrome
Diclofenac sodium gel 1%	Phase 3	Osteoarthritis, Knee
tolterodine extended release capsule	Phase 3	Urinary Incontinence
MR-130A-01 Transdermal patch	Phase 2	Contraception
MR-107A-02	Phase 2	Acute Pain
Venlafaxine ER	Phase 3	Major Depressive Disorder
Venlafaxine XR	Phase 3	Anxiety
Xalacom	Phase 3	Glaucoma, Open Angle
Mylan's insulin glargine	Phase 3	Type 1 Diabetes
Lantus®	Phase 3	Type 2 Diabetes

Price & technical context

3-month

-6.0%

6-month

+2.8%

12-month

+51.8%

52-wk range

$9.49–$17.86

vs 50-day MA

-2.1%

vs 200-day MA

+13.7%

Realized vol

31.7%

Max drawdown

-45.7%

Daily closes through 2026-08-14. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VTRS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.